, Population pharmacokinetics of nevirapine in combination with 2 rifampicin-based short course chemotherapy in HIV-and tuberculosis-infected 3, 2009.
, 5 Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase 6 inhibitor nevirapine by human hepatic cytochromes P-450, Drug Metab Dispos, vol.7, issue.8, pp.1488-1495, 1999.
, CYP3A5 genotype has no impact on plasma trough concentrations of 10 lopinavir and ritonavir in HIV-infected subjects, Clin Pharmacol Ther, vol.9, issue.11, pp.205-207, 2008.
, Positive outcomes of HAART at 24 months in HIV-infected 14 patients in Cambodia, Aids, vol.21, issue.15, pp.2293-2301, 2007.
, Nonnucleoside Reverse Transcriptase Inhibitor Pharmacokinetics in a Large Unselected Cohort of HIV-Infected Women, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.50, issue.5, pp.482-501, 2009.
DOI : 10.1097/QAI.0b013e31819c3376
, Successful efavirenz dose reduction in 24 HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect 25 Dis, pp.1230-1237, 2007.
, High variability of indinavir and nelfinavir pharmacokinetics 29 in HIV-infected patients with a sustained virological response on highly active 30 antiretroviral therapy, Clin Pharmacokinet, vol.44, issue.20, pp.1267-1278, 2005.
, Intra-and 32 inter-ethnic differences in the allele frequencies of, 2006.
, Associations between 36 CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or 37 efavirenz in African americans, J Infect Dis, vol.35, issue.38, pp.872-880, 2009.
, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult 41 AIDS Clinical Trials Group study, 43 Kishikawa, M. Matsuura, Y. Agatsuma, T. Inoue, and M. Mizugaki, pp.2391-2400, 2002.
, CYP3A5 genotype has an impact on the metabolism of the HIV 3 protease inhibitor saquinavir, Clin Pharmacol Ther, vol.81, issue.4, pp.708-712, 2007.
, Genetic variability of 6 CYP2B6 in populations of African and Asian origin: allele frequencies, novel 7 functional variants, and possible implications for anti-HIV therapy with efavirenz, 2005.
, Single dose pharmacokinetics and 11 bioavailability of nevirapine in healthy volunteers, Pharmacogenet Genomics. Biopharm Drug Dispos, vol.15, issue.27, pp.861-873285, 1999.
, Effectiveness and safety 17 of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in 18 HIV-1-infected adults in Cameroon: open-label multicentre trial Cytochrome P450 2B6 516G-->T is associated with 22 plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once 23 daily in an ethnically diverse population, Lancet. HIV Med, vol.364, issue.24, pp.29-48, 2004.
, A 30 randomized trial comparing plasma drug concentrations and efficacies between 2 31 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected 32 patients receiving rifampicin: the N2R Study, Clin Infect Dis, vol.48, issue.31, pp.1752-1759, 2009.
, Pharmacokinetics 35 of lamivudine, zidovudine, and nevirapine administered as a fixed-dose 36 combination formulation versus coadministration of the individual products, J Clin 37 Pharmacol, vol.47, issue.32, pp.1381-1389, 2006.
, Once-or twice-daily dosing of 43 nevirapine in HIV-infected adults: a population pharmacokinetics approach, p.44, 2008.
, Marked 2 intraindividual variability in antiretroviral concentrations may limit the utility of 3 therapeutic drug monitoring, Clin Infect Dis, vol.42, issue.35 5, pp.1189-1196, 2006.
, Evaluation of the genetic component of 6 variability in CYP3A4 activity: a repeated drug administration method, Mbamanya, V. Natarajan, R. M. 9, pp.373-388, 2000.
, Cytochrome P450 2B6 10 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected 11 patients in Uganda Mixed-Effects Models in S and S-PLUS, 1st 13 edition ed, 14 38. Puthanakit, T., P. Tanpaiboon, L. Aurpibul, T. R. Cressey, and V. 15, pp.86-91, 2000.
, Plasma efavirenz concentrations and the association with 16 CYP2B6-516G >T polymorphism in HIV-infected Thai children, Antivir Ther, vol.17, issue.18, pp.315-320, 2009.
, Genetic Polymorphism on Tacrolimus Daily Dose Requirements and Acute Rejection in Renal Graft Recipients, Basic & Clinical Pharmacology & Toxicology, vol.18, issue.Suppl. 1, pp.546-552, 2008.
DOI : 10.1111/j.1742-7843.2008.00327.x
, Influence of CYP2B6 24 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz 25 and nevirapine in HIV-infected patients, Pharmacogenet Genomics, vol.23, issue.41, pp.1-5, 2005.
, Impact 30 of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the 31, 2007.
, CYP2B6 genetic 39 variants are associated with nevirapine pharmacokinetics and clinical response in 40 HIV-1-infected children, Aids, vol.21, pp.2191-2199, 2007.
, Minimal effect of MDR1 and CYP3A5 genetic 44 polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients, Br J, p.45, 2007.
, Adherence to 2 antiretroviral therapy in patients enrolled in a comprehensive care program in 3, 2008.
, Pharmacogenetics of Anti-HIV Drugs, Annual Review of Pharmacology and Toxicology, vol.48, issue.1, 2008.
DOI : 10.1146/annurev.pharmtox.48.113006.094753
, Analysis of East Asia genetic substructure using genome-wide 8 SNP arrays, 2008.
, High-performance liquid chromatographic method for the 11 simultaneous determination of the six HIV-protease inhibitors and two non- 12 nucleoside reverse transcriptase inhibitors in human plasma, Ther Drug Monit, vol.13, issue.14, pp.417-424, 2002.
, Population 20 pharmacokinetics of nevirapine, zidovudine, and didanosine in human 21 immunodeficiency virus-infected patients, The National Institute of Allergy and 22 Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. 23 Antimicrob Agents Chemother, pp.121-128, 1999.